Get the Daily Brief
Latest Biotech News
Roche, Freenome tie-up and new sequencer — diagnostics push abroad
Roche agreed to a collaboration and licensing deal with Freenome worth potentially more than $200 million to commercialize Freenome’s blood-based cancer screening tests outside the U.S.; Roche...
Nvidia, Sheba, Mount Sinai to build genomic foundation model
Nvidia, Sheba Medical Center’s ARC Innovation and the Icahn School of Medicine at Mount Sinai launched a three‑year collaboration to develop a large language model (genomic Foundation Model, gFM)...
DNAe readies rapid sequencing platform — LiDia‑SEQ commercialization set for 2027
UK diagnostics firm DNA Electronics presented data supporting its LiDia‑SEQ rapid sequencing platform and said it plans commercialization in 2027, targeting same‑day infectious-disease and cancer...
Venture capital surge: Iambic $100M; Solve nets $120M for ADCs
Iambic closed a $100 million financing to accelerate AI drug‑discovery platforms (Enchant and NeuralPLexer) and move cancer candidates toward the clinic; investors include Abingworth and...
NIH cuts halted 383 trials — 74,000 participants affected
A JAMA Internal Medicine analysis found that federal funding cuts led to termination of 383 NIH‑funded clinical trials between late February and mid‑August, disrupting more than 74,000 enrolled...
Administration probes vaccine reform: makers warn of supply shock
U.S. health-policy proposals under the Trump administration and Health Secretary Robert F. Kennedy Jr. are prompting vaccine manufacturers to raise concerns about rapid, wide-ranging changes to...
Roche’s SERD wins in early breast cancer – adjuvant data positive
Roche reported positive Phase 3 data for its oral selective estrogen receptor degrader (SERD) giredestrant in the adjuvant setting for ER-positive, HER2-negative early breast cancer. At a...
Zanidatamab cuts progression in Phase 3 — partners set regulatory push
Zymeworks and Jazz Pharmaceuticals announced positive topline results from the Phase 3 HERIZON-GEA-01 trial evaluating zanidatamab (Ziihera) in first-line HER2-positive gastroesophageal...
J&J shells out $3.05B for Halda’s RIPTAC platform
Johnson & Johnson agreed to acquire Halda Therapeutics for $3.05 billion in cash to gain the company's regulated induced proximity targeting chimera (RIPTAC) technology and lead candidate HLD-0915...
Merck buys Cidara for $9.2B — long-acting, strain-agnostic flu candidate in focus
Merck agreed to acquire Cidara Therapeutics for $9.2 billion to secure CD388, a late-stage investigational long-acting, strain-agnostic antiviral designed to prevent symptomatic influenza in...
Roche invests in Freenome: $75M stake, ex-US commercialization deal
Roche and Freenome struck a multiyear collaboration that gives Roche exclusive rights to develop and commercialize kit-based versions of Freenome's blood-based cancer screening tests outside the...
Iambic raises $100M to scale AI drug discovery and bring candidates to clinic
Iambic closed an oversubscribed $100 million financing round to expand its AI platforms Enchant and NeuralPLexer and advance cancer drug candidates. The company says Enchant predicts clinical and...
DNAe targets 2027 launch for LiDia-SEQ: same-day bloodstream infection sequencing
UK molecular-diagnostics firm DNA Electronics presented data supporting its LiDia-SEQ rapid sequencing platform and announced plans to commercialize the cartridge-based instrument in 2027. Company...
Nordic Capital takes majority stake in Evosep to push proteomics into clinic
Private equity firm Nordic Capital acquired an 80% stake in Danish proteomics company Evosep to accelerate the firm's push into translational and clinical proteomics markets. CEO Morten Bern said...
TCR momentum: Captain T Cell funds pipeline and T-knife files CTA for solid tumors
Two developments underscore renewed investor and clinical momentum in T-cell receptor (TCR) therapies for solid tumors. Captain T Cell closed an equity financing round to advance its autologous...
J&J snaps up Halda for $3.05B — acquires RIPTAC 'hold-and-kill' platform
Johnson & Johnson agreed to acquire Halda Therapeutics for $3.05 billion in cash, securing Halda’s regulated induced proximity targeting chimera (RIPTAC) platform and lead candidate HLD-0915 for...
Zanidatamab clears phase 3 barrier — two positive reads reshape HER2 GEA market
Zymeworks, in partnership with Jazz Pharmaceuticals and BeOne, reported positive topline results from the Phase 3 HERIZON‑GEA‑01 study: zanidatamab (Ziihera) plus chemotherapy improved...
Merck buys Cidara for $9.2B — aims at long‑acting, strain‑agnostic influenza prevention
Merck agreed to acquire Cidara Therapeutics for $9.2 billion to add CD388, a long‑acting, strain‑agnostic antiviral advancing in Phase III for influenza prevention in high‑risk populations. CD388...
Roche inks licensing pact with Freenome — $75M equity, ex‑US commercialization rights
Roche and Freenome signed a collaboration that could exceed $200 million, including a $75 million Roche equity investment, giving Roche exclusive ex‑US rights to develop distributed, kit‑based...
Iambic raises $100M — AI platform funding to move oncology candidates into clinic
Iambic closed an oversubscribed $100 million financing led by Abingworth and Alexandria Ventures to accelerate its multimodal AI drug discovery stack and advance cancer candidates toward the...